|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,712.50 DKK | +3.22% |
|
-1.35% | -15.52% |
| 07:35am | Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target | FW |
| 05-11 | Deutsche Bank trims Genmab price target to DKK 2,250 (2,400), reiterates Buy | FW |
Company Valuation: Genmab A/S
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 172,063 | 192,229 | 140,770 | 94,810 | 124,862 | 101,848 | - | - |
| Change | - | 11.72% | -26.77% | -32.65% | 31.7% | -18.43% | - | - |
| Enterprise Value (EV) 1 | 152,725 | 169,905 | 112,635 | 73,709 | 114,029 | 121,804 | 110,977 | 100,083 |
| Change | - | 11.25% | -33.71% | -34.56% | 54.7% | 6.82% | -8.89% | -9.82% |
| P/E ratio | 57.8x | 35.2x | 32.6x | 12.3x | 20.9x | 22.6x | 15.3x | 9.72x |
| PBR | 7.82x | 7.07x | 4.5x | 2.68x | 3.47x | 2.52x | 2.16x | 1.78x |
| PEG | - | 0.4x | -1.5x | 0.1x | -1x | -0.9x | 0.3x | 0.2x |
| Capitalization / Revenue | 20.3x | 13.2x | 8.54x | 4.4x | 5.31x | 3.71x | 3.15x | 2.55x |
| EV / Revenue | 18x | 11.6x | 6.84x | 3.42x | 4.85x | 4.44x | 3.43x | 2.51x |
| EV / EBITDA | 46.8x | 25.3x | 20.1x | 10.4x | 15.9x | 14.6x | 9.68x | 6.09x |
| EV / EBIT | 50.6x | 26.7x | 21.2x | 10.5x | 17x | 16.4x | 11.4x | 6.91x |
| EV / FCF | 77.3x | 47.3x | 16.1x | 9.72x | 15.7x | 19.9x | 11.9x | 6.48x |
| FCF Yield | 1.29% | 2.12% | 6.23% | 10.3% | 6.36% | 5.02% | 8.41% | 15.4% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 45.54 | 83.65 | 66.02 | 121.4 | 97.08 | 73.46 | 108.2 | 170.7 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 8,482 | 14,595 | 16,474 | 21,526 | 23,497 | 27,464 | 32,351 | 39,884 |
| EBITDA 1 | 3,266 | 6,719 | 5,616 | 7,116 | 7,175 | 8,334 | 11,464 | 16,423 |
| EBIT 1 | 3,018 | 6,357 | 5,321 | 7,003 | 6,727 | 7,413 | 9,752 | 14,485 |
| Net income 1 | 3,008 | 5,522 | 4,352 | 7,844 | 6,083 | 4,607 | 7,026 | 10,962 |
| Net Debt 1 | -19,338 | -22,324 | -28,135 | -21,101 | -10,833 | 19,956 | 9,129 | -1,764 |
| Reference price 2 | 2,630.00 | 2,941.00 | 2,155.00 | 1,492.50 | 2,027.00 | 1,659.00 | 1,659.00 | 1,659.00 |
| Nbr of stocks (in thousands) | 65,423 | 65,362 | 65,322 | 63,524 | 61,599 | 61,391 | - | - |
| Announcement Date | 16/02/22 | 22/02/23 | 14/02/24 | 12/02/25 | 17/02/26 | - | - | - |
1DKK in Million2DKK
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 22.82x | 4.44x | 14.61x | -.--% | 16.06B | |
| 28.75x | 7.55x | 22.58x | -.--% | 50.65B | |
| 18x | 5.52x | 12.07x | 1.65% | 48.58B | |
| -17.95x | 3.48x | -6.34x | -.--% | 23.6B | |
| -38.59x | 12.9x | -34.98x | -.--% | 22.52B | |
| 21.67x | 4.28x | 11.11x | -.--% | 17.47B | |
| 817.74x | 19.27x | 105.56x | -.--% | 15.45B | |
| -15.63x | 4112.17x | -19.09x | -.--% | 14.48B | |
| -452.98x | 32.5x | -2035.42x | -.--% | 13.38B | |
| 15.74x | 4.52x | 10.59x | -.--% | 12.49B | |
| Average | 39.96x | 420.66x | -191.93x | 0.17% | 23.47B | |
| Weighted average by Cap. | 35.47x | 262.12x | -104.50x | 0.34% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- GMAB Stock
- Valuation Genmab A/S
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition